{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:20:45Z","timestamp":1787498445394,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Novel therapies are needed for patients with multiple myeloma (MM) and extramedullary plasmacytomas. The prospective, Phase II EMN19 study assessed the efficacy and safety of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (DaraVCD) in 40 patients with newly diagnosed MM (NDMM;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200929) or at first relapse (RMM;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911) and positron emission tomography or computed tomography (PET\/CT)\u2010confirmed extramedullary plasmacytomas (extraosseous [EMD] and\/or paraosseous [PS]). DaraVCD was administered until disease progression or up to 3 years. The primary endpoint was hematological complete response (CR). Among patients, 22 (55.0%), 4 (10.0%), and 14 (35.0%) had EMD, EMD\/PS, and PS plasmacytomas, respectively. Median patient age was 58.0 years, and 16 (40.0%), 12 (30.0%), and 10 (25.0%) patients were at International Staging System (ISS) Stages I, II, and III, respectively. Median circulating tumor cell (CTC) level was 0.002% (range, 0.000\u20130.353), significantly higher (P\u2009&lt;\u20090.05) in patients with ISS Stage III and those with plasma cells\u2009&gt;\u200960%. At a median follow\u2010up of 30.0 months, all patients completed treatment (median duration: 19.8 months). The overall hematologic \u2265CR rate was 47.5% (19\/40; NDMM patients: 58.6% [17\/29]; RMM patients: 18.2% [2\/11]). Of patients with \u2265CR, 80.0% (15\/19) achieved minimal residual disease (MRD) negativity, and 68.4% (13\/19) combined MRD negativity and complete metabolic response (CMR) on PET\/CT. The overall median progression\u2010free survival was 25.8 months, significantly longer in patients achieving hematologic \u2265CR and\/or CMR than others (not reached and 4.8 months, respectively; P\u2009&lt;\u20090.001). DaraVCD showed encouraging efficacy in patients with MM and extramedullary plasmacytomas. Notably, this is the first report on CTC levels in EMD, and they were lower than previously reported NDMM thresholds.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70287","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:29:32Z","timestamp":1767860972000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Daratumumab\u2010based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"first","affiliation":[{"name":"Department of Hematology Istinye University, Ankara Liv Hospital Ankara Turkey"},{"name":"Department of Hematology Ankara University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulin","family":"F\u0131ratl\u0131 Tuglular","sequence":"additional","affiliation":[{"name":"Department of Hematology Marmara University Faculty of Medicine Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"University of Torino, Azienda Ospedaliero\u2010Universitaria Citt\u00e0 della Salute e della Scienza di Torino Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[{"name":"University of Torino, Azienda Ospedaliero\u2010Universitaria Citt\u00e0 della Salute e della Scienza di Torino Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-807X","authenticated-orcid":false,"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology Theagenio Cancer Hospital Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine Erciyes University Melikgazi Kayseri Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guner Hayri","family":"Ozsan","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine, School of Medicine Dokuz Eylul University Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent H. J.","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna H.","family":"Beverloo","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van Duin","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guldane Cengiz","family":"Seval","sequence":"additional","affiliation":[{"name":"Department of Hematology Ankara University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omur Gokmen","family":"Sevindik","sequence":"additional","affiliation":[{"name":"Department of Hematology Medipol University Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Merante","sequence":"additional","affiliation":[{"name":"European Myeloma Network Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Manousou","sequence":"additional","affiliation":[{"name":"Veeda LifeSciences Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17338"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106948"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2281657"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.278272"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0660-0"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.582"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79537-2"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01374-5"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27023"},{"key":"e_1_2_13_17_1","unstructured":"Darzalex summary of product characteristics. European Medicines Agency. Accessed June 8 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf"},{"key":"e_1_2_13_18_1","unstructured":"Darzalex summary of product characteristics. Food and Drug Administration. Accessed June 8 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761036s041lbl.pdf"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15806"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1859263"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3200-9"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00386"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2076847"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012539"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102017"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01231"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406536"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199542"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115374"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01393"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01365"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70287","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T16:08:43Z","timestamp":1771171723000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/hem3.70287"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70287","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70287"}}